Caris Life Sciences vs Guardant Health
CAI and GH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAI and GH compare
Guardant Health is the larger company, worth 3.1 times as much as Caris Life Sciences ($20.4B against $6.5B).
Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 41.7% for Guardant Health).
Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −37.9% at Guardant Health.
Guardant Health scores higher on the StockData Score (10 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAI | GH |
|---|---|---|
| Size and price | ||
| Market cap | $6.5B | $20.4B |
| Share price | $23.04 | $151.70 |
| Change, 1 year | −7.0% | 55.0% |
| Change, 5 years | – | 55.5% |
| Beta (5Y) | 2.21 | 1.62 |
| Employees | 1,846 | 2,506 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 3 (better) | 1 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.2× (better) | 15.9× |
| P/B | 10.2× | – |
| EV/EBITDA | 41.9× | – |
| P/FCF | 225× | – |
| FCF yield | 0.44% (better) | −1.1% |
| Fair value | $10.40 | – |
| Margin of safety | −121% | – |
| Growth | ||
| Revenue growth (TTM) | 61.5% (better) | 41.7% |
| Revenue growth, 5Y average | – | 27.9% |
| Profitability | ||
| Gross margin | – | 65.2% |
| Operating margin | 13.4% (better) | −39.4% |
| Net margin | 9.2% (better) | −37.9% |
| FCF margin | 2.8% (better) | −18.2% |
| Return on equity | 17.2% | – |
| Return on invested capital | 26.8% | – |
| Financial health | ||
| Debt / equity | 0.61 | – |
| Net debt / EBITDA | 1.79 | – |
| Interest coverage | 3.3× (better) | −96.6× |
| Current ratio | 6.71 (better) | 3.60 |
| Altman Z-score | 5.58 (better) | 3.58 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Buyback yield | 0.48% (better) | 0.00% |
| Shareholder yield | 0.48% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 54.5% | 99.8% |
| Held by insiders | 64.1% | 1.8% |
| Insider net buying, 12 months | −$27.4M (better) | −$173M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 11.3% | 7.2% |
Go deeper
- CAI stock overview
- CAI income statement
- CAI valuation and score
- GH stock overview
- GH income statement
- GH valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.